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Abstract
Background: Leiomyosarcoma (LMS) is an aggressive soft tissue sarcoma derived from smooth muscle cells typically
of uterine, gastrointestinal or soft tissue origin.
The prognosis for this tumor is poor, with survival rates among the lowest of all soft tissue sarcomas. Surgery is the
best approach for localized disease. The principal role of chemotherapy is prevalently in the treatment of metastatic
disease. Trabectedin, a promising new DNA-damaging agent with a mechanism of action that differs from that of
traditional alkylating agents, has been approved in Europe for the treatment of patients with advanced soft tissue
sarcoma after failure of anthracyclines and ifosfamide,
Case presentation: We report the case of a 53-year-old woman with metastatic well differentiated uterine
leiomyosarcoma refractory to multiple treatments who underwent 22 cycles of trabectedin over 30 months,
obtaining a partial response according to RECIST (Response Evaluation Criteria in Solid Tumors) criteria, with good
tolerability, and maintaining the response for 10 months after trebectedin withdrawal.
Conclusion: This very prolonged response, which persisted after drug discontinuation, suggests that trabectedin
exerts an oncostatic effect rather than the cytotoxic one produced by other chemotherapeutic agents. Our
experience also raises the question of the best way to evaluate trabectedin efficacy.
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Background
Leiomyosarcomas (LMSs) constitute a wide group of
histopathologically heterogeneous tumors derived from
smooth muscle cells. These aggressive malignancies rep-
resent one of the most common types of soft tissue sar-
coma, with an incidence of 11 % [1]. LMSs are of
uterine origin in 50 % of cases but have also been re-
ported in the kidneys [2], pancreas [3], retroperitoneum
[4], thyroid [5], lungs [6], blood vessels [7] and skin [8].
In addition to various sites of origin, LMSs also show
substantial variability from a histological and morpho-
logical point of view and are classified into the following
subtypes: myxoid [9], epithelioid [10], dedifferentiated
[11], inflammatory [12], granular cell [13] and well dif-
ferentiated [14]. In the majority of cases, diagnosis is
made following hysterectomy or myomectomy per-
formed for presumably benign leiomyoma [15]. A high
incidence of local and distant relapse has also been re-
ported, even after complete resection [16].
The factors associated with poor prognosis include
age >62 years, tumor size > 4 cm, tumor necrosis,
Fédération Nationale des Centres de Lutte Contre le
Cancer (FNCLCC) grade, vascular invasion, or previous
intralesional surgery [17, 18]. Although the mitotic
index is not directly correlated with a worse outcome,
it is clearly a useful parameter to distinguish between
malignant and benign tumors. Furthermore, in a retro-
spective study of 66 patients with LMS, Mankin et al.
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reported that Musculoskeletal Tumor Society (MSTS)
stage and size had a significant impact on outcome,
whereas gender, age, site, adjuvant therapy and pres-
ence of local recurrence did not. Overall survival (OS)
reported for patients diagnosed with LMS ranges from
50 % at 3 years to 64 % at 5 years, making this tumor
one of the most aggressive forms of soft tissue sarcoma
(STS) [19].
The primary role of chemotherapy in LMS is to treat
metastatic disease; although not curative, it has been
shown to slow down disease progression. Drugs frequently
used include doxorubicin and ifosfamide, gemcitabine and
taxotere (docetaxel), dacarbazine, and trabectedin. Some
reviews have reported mortality rates ranging from 77 %
to 93 % for retroperitoneal/abdominal leiomyosarcoma
[20]. However, a number of studies with small case series
have provided a valuable insight into the prognostic sig-
nificance of some patient variables. A phase III clinical
trial comparing adjuvant chemotherapy composed of cis-
platin, ifosfamide and doxorubicin followed by radiother-
apy with radiotherapy alone in patients with localized
uterine sarcomas reported promising results in favor of
combined modalities, with a 3-year improvement in
progression-free survival (PFS) [21]. Other interesting
findings were obtained in a prospective phase II trial in-
vestigating the combination of gemcitabine and docetaxel
followed by doxorubicin in stage I/II LMS, the authors ob-
serving a 2-year PFS of 78 % [22]. In a study by Schmitt et
al., patients with unresectable leiomyosarcoma (n = 34),
mainly of the uterine type, received gemcitabine and doce-
taxel in combination [23]. Sixteen of the patients were
treated after progressing on doxorubicin-based therapy,
obtaining a 53 % response rate and a median time to pro-
gression (TTP) of 5.6 months. Hensley et al. used the
same regimen as second-line treatment for patients with
advanced uterine LMS [24]. Although the objective re-
sponse rate (ORR) (27 %) was lower than that of the first
trial, an additional 50 % of patients had stable disease (SD)
for a median of 5.4 months and the 24-week PFS rate was
52 %. Options in advanced or relapsed stages were evalu-
ated in a phase II clinical trial investigating ridaforolimus
(mTOR inhibitor) in bone and soft tissue sarcomas, and a
subsequent phase III trial analyzed the efficacy of the same
drug as maintenance therapy [25]. Furthermore, a non-
randomized phase II clinical trial evaluating eribulin in pa-
tients with advanced or metastatic sarcomas reported the
best treatment response to date [26]. Finally, results from
a randomized placebo-controlled phase III trial in patients
with metastatic and recurrent soft tissue sarcomas treated
with pazopanib revealed an increase in PFS with respect
to placebo [27].
Trabectedin (Yondelis®; PharmaMar, Madrid, Spain), is
a cytotoxic agent originally isolated from the Caribbean
sea squirt ecteinascidia turbinata and is currently
manufactured by total synthesis. With pleiotropic mech-
anisms of action, it binds to the DNA minor groove,
causing double helix bending towards the major groove,
modulating inflammatory responses in the tumor micro-
environment, and promoting tumor cell differentiation
[28]. The pivotal registration study of trabectedin was a
randomized phase II comparison (ET-743-STS-201 trial)
of two different schedules of trabectedin administered
either every 3 weeks (q3w) or weekly in anthracycline-
and ifosfamide-pretreated patients with LMS or liposar-
coma [29]. Data from the trial showed that trabectedin
1.5 mg/m2 given as a 24-h intravenous infusion in a
q3w-regimen obtained better disease control than
weekly trabectedin 0.58 mg/m2 (3-h infusion for three
consecutive weeks in a 4-week cycle) in terms of longer
TTP (median TTP: 3.7 vs. 2.3 months; P = 0.0302) and
PFS (median PFS: 3.3 vs. 2.3 months; P = 0.0418). Based
on these results, in 2007 trabectedin was approved for
the treatment of patients with advanced STS following
failure of anthracyclines and ifosfamide, and also for
those who were not amenable to treatment with these
drugs. A recent phase III trial showed no significant
difference in PFS or OS between trabectedin and
doxorubicin-based chemotherapy in selected patient
populations [30]. The histological heterogeneity of STS,
compounded by their rarity, poses particular challenges
in personalizing therapy.
In the absence of large randomized studies, institu-
tional case series can provide useful insights into the ef-
ficacy, toxicity and management of patients receiving
novel agents. In this paper we describe the case of a 53-
year-old woman with LMS in progression after several
treatments who obtained a durable response with tra-
bectedin that persisted after the drug was withdrawn.
Case presentation
We report the case of a 53-year-old woman who was re-
ferred to our Institute with a history of myomectomy in
1997, 2003 and 2004, and hysterectomy in 2006 follow-
ing a diagnosis of well differentiated, estrogen receptor
(ER)-positive uterine LMS. In November 2006 a CT scan
revealed several peritoneal lesions which were surgically
removed. The pathology report described several locali-
zations of well differentiated uterine leiomyosarcoma
(20 % estrogen and 80 % progesterone receptor-
positive). Five cycles of chemotherapy with adriamycin
and ifosfamide were administered, with no signs of re-
currence. In 2007, the patient underwent ovariectomy
and metastasectomy for multiple lung lesions and then
entered follow-up. In 2009, a CT scan showed abdominal
and rectal recurrence and the patient was submitted to
omentectomy with the removal of omental nodules,
mesosigma and rectum. Somatostatin-receptor scintig-
raphy (Octreoscan) revealed positivity of abdominal
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lesions and the patient was enrolled onto a phase I clin-
ical trial, receiving 5 cycles of 177Lu radioreceptor
DOTATATE. Treatment lasted from September 2009 to
May 2010, with a cumulative dose of 610 mCi. CT
evaluation after the last treatment cycle showed disease
progression in the pleura, lungs and abdomen. It was
thus decided to start weekly gemcitabine alternating
with 3 cycles of peritoneal hyperthermia, the latter per-
formed in a different institution. After two cycles of
chemotherapy, a CT scan showed peritoneal progression
(Fig. 1) and stability of the lung metastases. In March
2011 the patient began treatment with trabectedin at a
dose of 1.5 mg/m2 administered as a 24-h intravenous
infusion every 3 weeks. Each infusion was preceded by
500 ml of 0.9 % sodium chloride and 20 mg dexametha-
sone given intravenously and followed by a short course
of prednisone.
Treatment with trabectedin continued until November
2012 (total of 22 cycles), the patient obtaining a partial re-
sponse according to RECIST criteria confirmed 11 months
after the start of treatment (Fig. 2). Hematological toxicity
was limited to grade 1-2 reversible neutropenia and an
isolated episode of grade 3 hyper-transaminasemia
after the third cycle of treatment. In October 2012,
after a CT scan revealed a slight dimensional increase
in the abdominal lesions, the patient decided to ask for
a second opinion at another institute where it was pro-
posed to withdraw trabectedin and begin a new course
of chemotherapy with dacarbazine for 3 cycles. In
December 2012, before starting dacarbazine, the pa-
tient underwent a CT scan which confirmed the stabil-
ity of the peritoneal disease but highlighted an increase
in the size of a previously documented single lesion in
the right abdominal wall. Surgery was performed and a
histological diagnosis was made of grade 3 leiomyosar-
coma according to FNCLCC criteria with several nec-
rotic foci representing less than 50 % of the lesion.
Two months later, imaging studies re-confirmed stable
disease in the peritoneum. However, in September
2013, 10 months after the last cycle of trabectedin and
30 months after the start of treatment, a CT scan
showed abdominal and peritoneal progression (Fig. 3),
and it was decided to proceed with pazopanib. Treat-
ment is ongoing.
Discussion
Leiomyosarcoma is an aggressive STS derived from
smooth muscle cells typically of uterine or gastrointes-
tinal origin. STS have a number of histologic subtypes
including epithelioid, myxoid, inflammatory, granular
cell and dedifferentiated, but the clinical impact of these
subtypes has not been widely investigated. The present
report describes the rare case of a patient with heavily
pretreated metastatic uterine LMS who received trabec-
tedin and showed a partial response according to
RECIST criteria that persisted for 10 months after drug
Fig. 1 January 2011: CT scan showing peritoneal progression after gemcitabine
Bongiovanni et al. BMC Cancer  (2015) 15:998 Page 3 of 6
Fig. 2 July 2012 (11 months after the start of treatment): CT scan showing a reduction in the size of the abdominal lesions
Fig. 3 September 2013: CT scan showing abdominal progression with an increase in the size of the peritoneal lesions
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withdrawal (30 months after the start of treatment), with
good tolerability.
Trabectedin is a substance derived from a type of mar-
ine invertebrate. Its mechanisms of action are based on
an interaction with the minor groove of the DNA double
helix which affects gene transcription and DNA repair
pathways, resulting in G2-M cell cycle arrest and ultim-
ately apoptosis. It is currently used in previously treated
advanced soft-tissue sarcoma. The median overall sur-
vival of patients with STS is 6 months in unresectable or
metastatic disease that progresses after treatment with
anthracyclines and ifosfamide. Recently, a retrospective
analysis of 66 patients with metastatic uterine LMS, the
majority in progression after 2-3 different treatments, re-
ported that 11 patients achieved a radiological partial re-
sponse according to RECIST criteria and a further 23
demonstrated stable disease following treatment with
trabectedin [31]. Galizia et al. described a rare case of
17-month disease stability in a 76-year-old patient with
progressive metastatic lung lesions from previously
resected primary LMS of the thigh who underwent
third-line treatment with 22 cycles of trabectedin [32].
Conventional chemotherapy is usually administered
for a limited period because its efficacy decreases over
time and because of cumulative toxicities. In particular,
cardiotoxicity from anthracycline-based regimens and
renal and neuronal toxicities from other chemotherapeu-
tic agents such as ifosfamide and cisplatin can negatively
affect subsequent therapeutic options and quality of life
[33–35]. In our case, the main toxicities reported were
mild neutropenia and reversible hyper-transaminasemia,
in agreement with the safety profile of trabectedin. This
allowed trabectedin to be administered for a long period
without cumulative toxicity and with an acceptable qual-
ity of life for the patient. Disease control was maintained
over time, impacting overall survival.
The very prolonged response obtained suggests that
trabectedin may be capable of keeping tumor cell
growth under control and is indicative of an oncostatic
effect rather than the cytotoxic action previously asso-
ciated with this drug. Recent data have shown that tra-
bectedin selectively targets mononuclear phagocytes,
including tumor-associated macrophages, and downre-
gulates the production of pro-inflammatory mediators
which induces changes in the tumor microenvironment
and contributes to its antitumor activity. This immuno-
modulating effect with high anti-inflammatory and
antiangiogenic activity may explain the durable re-
sponse experienced by our patient.
Conclusions
The low toxicity profile of trabectedin permitted us to
continue treatment for a lengthy period and the re-
sponse achieved was maintained by the patient for
several months after its withdrawal. Thus, decreased
tumor volume is clearly not the only criteria with which
to define trabectedin activity. Future clinical trials could
investigate the methods to define response to trabecte-
din and it could also be hypothesized to use the drug as
maintenance therapy to positively impact the overall sur-
vival of patients with soft tissue sarcoma.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor of this journal.
Abbreviations
LMS: Leiomyosarcoma; STS: Soft tissue sarcoma; FNCLCC: Fédération
Nationale des Centres de Lutte Contre le Cancer; PFS: Progression-free
survival; ORR: Objective response rate; SD: Stable disease; TTP: Time-to-
progression; OS: Overall survival; CT: Computerized tomography;
MSTS: Musculoskeletal tumor society; RECIST: Response evaluation criteria in
solid tumors.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors contributed equally to this paper and approved its submission for
publication.
Acknowledgements




1Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo
Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. 2Unit of Surgery and
Advanced Oncologic Therapies, Morgagni-Pierantoni Hospital, Forlì, Italy.
3Pathology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy. 4Radiology Unit,
IRST IRCCS, Meldola, Italy.
Received: 22 February 2015 Accepted: 20 December 2015
References
1. Ducimetière F, Lurkin A, Ranchère-Vince D, Decouvelaere AV, Péoc'h M,
Istier L, et al. Incidence of sarcoma histotypes and molecular subtypes in a
prospective epidemiological study with central pathology review and
molecular testing. PLoS One. 2011;6:e20294.
2. Terada T. Leiomyoma of the kidney parenchyma. Pathol Int. 2011;61:495–97.
3. Moletta L, Sperti C, Beltrame V, Gruppo M, Blandamura S, Pasquali C, et al.
Leiomyosarcoma of the pancreas with liver metastases as a paradigm of
multimodality treatment: case report and review of the literature. J Gastrointest
Cancer. 2012;43:246–50.
4. Chen J, Wei R, Ma X. Orbital metastasis of retroperitoneal leiomyosarcoma.
Med Oncol. 2012;29:392–5.
5. Tanboon J, Keskool P. Leiomyosarcoma: a rare tumor of the thyroid. Endocr
Pathol. 2013;24:136–43.
6. Elouazzani H, Zouaidia F, Jahid A, Bernoussi Z, Mahassini N. Primary
endobronchial leiomyosarcoma of the lung: clinical, gross and microscopic
findings of two cases. J Clin Imaging Sci. 2012;2:35.
7. Gage MJ, Newman E, Maldonado TS, Hajdu CH. Leiomyosarcoma of the
splenic vein. J Vasc Surg. 2012;55:1485–7.
8. Lee KC, Kim MS, Choi H, Na CH, Shin BS. Rapid growing superficial
cutaneous leiomyosarcoma of the face. Ann Dermatol. 2013;25:237–41.
Bongiovanni et al. BMC Cancer  (2015) 15:998 Page 5 of 6
9. Burch DM, Tavassoli FA. Myxoid leiomyosarcoma of the uterus. Histopathology.
2011;59:1144–55.
10. Teixeira V, Cardoso JC, Vieira R, Julião MJ, Figueiredo A. Epithelioid
leiomyosarcoma arising in the subcutis-a new case report of a rare variant.
Am J Dermatopathol. 2014;36:603–5.
11. Nicolas MM, Tamboli P, Gomez JA, Czerniak BA. Pleomorphic and
dedifferentiated leiomyosarcoma: clinicopathologic and
immunohistochemical study of 41 cases. Hum Pathol. 2010;41:663–71.
12. Nord KH, Paulsson K, Veerla S, Wejde J, Brosjö O, Mandahl N, et al. Retained
heterodisomy is associated with high gene expression in hyperhaploid
inflammatory leiomyosarcoma. Neoplasia. 2012;14:807–12.
13. Sironi M, Assi A, Pasquinelli G, Cenacchi G. Not all granular cell tumors show
schwann cell differentiation: a granular cell leiomyosarcoma of the thumb, a
case report. Am J Dermatopathol. 1999;21:307–9.
14. Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB.
Uterine sarcomas in Norway. A histopathological and prognostic survey of a
total population from 1970 to 2000 including 419 patients. Histopathology.
2009;54:355–64.
15. El-Khalfaoui K, du Bois A, Heitz F, Kurzeder C, Sehouli J, Harter P. Current
and future options in the management and treatment of uterine sarcoma.
Ther Adv Med Oncol. 2014;6:21–8.
16. Reed N, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S.
European Organisation for Research and Treatment of Cancer
Gynaecological Cancer Group: Phase III randomised study to evaluate the
role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas
stages I and II. Group Study (protocol 55874). Eur J Cancer. 2008;44:808–18.
17. Gustafson P, Willén H, Baldetrop B, Fernö M, Akerman M, Rydholm A. Soft
tissue leiomyosarcoma: a population-based epidemiologic and prognostic
study of 48 patients, including cellular DNA content. Cancer. 1992;70:114.
18. Farshid G, Goldblum J, Weiss SW. Leiomyosarcoma of soft tissue: a tumor of
vascular origin with multivariate analysis of outcome. Mod Pathol. 2003;16:778–85.
19. Mankin HJ, Casas-Ganem J, Kim JI, Gebhardt MC, Hornicek FJ, Zeegen EN.
Leiomyosarcoma of somatic soft tissues. Clin Orthop Relat Res. 2004;421:225–31.
20. No authors listed. Adjuvant chemotherapy for localized respectable soft
tissue sarcoma of adults: meta analysis of individual data. Sarcoma Meta-
analysis Collaboration. Lancet 1997;350:1647
21. Pautier P, Floquet A, Gladieff L, Bompas L, Ray-Coquard I, Piperno S, et al.
A randomized clinical trial of adjuvant chemotherapy with doxorubicin,
ifosfamide and cisplatin followed by radiotherapy versus radiotherapy alone
in patients with localized uterine sarcomas (SARCGYN study). A study of the
French Sarcoma Group. Ann Oncol. 2012;24:1099–104.
22. Hensley M, Wathen J, Maki R, Anrojo DM, Sutton DA, Priebat DA, et al.
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: Results of
a phase 2 trial (SARC 005). Cancer. 2013;119:1555–61.
23. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C,
et al. Gemcitabine and docetaxel in patients with unresectable
leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824–31.
24. Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley HD.
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for
metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II
study. Gynecol Oncol. 2008;109:323–8.
25. Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ,
et al. Phase II study of the mammalian target of rapamycin inhibitor
ridaforolimus in patients with advanced bone and soft tissue sarcomas.
J Clin Oncol. 2012;30:78–84.
26. Schöffski P, Ray Coquard IL, Cioffi A, Bin Bui N, Bauer S, Hartmann JT. Activity of
eribulin mesylate in patients with soft tissue sarcome: a phase 2 study in four
independent histological subtypes. Lancet Oncol. 2011;12:1045–52.
27. Van der Graaf W, Blay J, Chawla S, Kim D, Bui-Nguyen B, Casali P, et al.
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised,
double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:18879–86.
28. D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique
mechanism of action. Mol Cancer Ther. 2010;9:2157.
29. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, et al.
Efficacy and safety of trabectedin in patients with advanced or metastatic
liposarcoma or leiomyosarcoma after failure of prior anthracyclines and
ifosfamide: results of a randomized phase II study of two different
schedules. J Clin Oncol. 2009;27:4188–96.
30. Blay JY, Leahy MG, Nguyen BB, Patel SR, Hohenberger P, Santoro A, et al.
Randomised phase III trial of trabectedin versus doxorubicin-based
chemotherapy as first-line therapy in translocation-related sarcomas.
Eur J Cancer. 2014;50:1137–47.
31. Sanfilippo R, Grosso F, Jones RL, Banerjee S, Pilotti S, D'Incalci M, et al.
Trabectedin in advanced uterine leiomyosarcomas: a retrospective case
series analysis from two reference centers. Gynecol Oncol. 2011;123:553–6.
32. Galizia D, Palesandro E, Nuzzo AM, Pignochino Y, Aliberti S, Aglietta M, et al.
Prolonged disease stability with trabectedin in a heavily pretreated elderly
patient with metastatic leiomyosarcoma of the thigh and renal failure: a
case report and review of the literature. Oncol Res. 2013;20:483–90.
33. Riedel RF. Systemic therapy for advanced soft tissue sarcomas: highlighting
novel therapies and treatment approaches. Cancer. 2012;118:1474–8.
34. Ferreira AL, Matsubara LS, Matsubara BB. Anthracycline-induced
cardiotoxicity. Cardiovasc Hematol Agents Med Chem. 2008;6:278–81.
35. Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C,
et al. High-dose ifosfamide: circumvention of resistance to standard-dose
ifosfamide in advanced soft tissue sarcomas. J Clin Oncol. 1995;13:1600–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Bongiovanni et al. BMC Cancer  (2015) 15:998 Page 6 of 6
